Most importantly, BCL9-2 expression correlated with hormone receptor positivity of the cancers: Triple negative breast cancers showed no BCL9-2 overexpression, but BCL9-2 was elevated in Her2 positive tumors, confirming a previous study [58]. Here, ERBB2 is linked to breast carcinoma.